Blood levels of cefazolin and cephalothin were determined in two separate crossover studies in 20 healthy male adults, each after intravenous and intramuscular administration. Pharmacokinetic parameters were calculated from the intravenous data based upon a two-compartment open model. The rate constants controlling the distribution between the central and peripheral compartments, the overall elimination rate constants, the apparent volumes of distribution, and the fraction of the dose in the central and peripheral compartments were determined. The bioavailability was calculated to be 100% for cefazolin and cephalothin.
Cefazolin is a new broad-spectrum cephalosporin antibiotic derived from 7-amino cephalosporanic acid, which has a wide range of activity against gram-positive and gram-negative pathogens. It was synthesized and studied extensively in Japan (6, 11-13, 16 ) before being developed for clinical use in the United States. Pharmacokinetic studies in normal subjects have shown higher and more prolonged serum levels with cefazolin than with other cephalosporin antibiotics, e.g., cephaloridine and cephalothin (3, 11, 16, 17) . While the drugs were under clinical investigation at Smith Kline & French Laboratories, a series of studies were undertaken to obtain additional human pharmacology data on cefazolin and compare it with cephalothin (2) .
It is the purpose of this paper to interpret the collected pharmacological data from these studies and to determine the pharmacokinetic parameters for cefazolin and cephalothin after 1-g intravenous and intramuscular injections. These parameters are important in evaluating pharmacokinetic differences within the cephaloporin class compounds, such as absorption and elimination rates, biological half-lives, serum-tissue distribution, distribution volumes, metabolic and renal clearance rates, and bioavailability.
MATERIALS AND METHODS
Crossover studies of cefazolin (Ancef; Smith Kline & French Laboratories) and cephalothin (Keflin; Eli Lilly & Co.) were carried out on two different groups of volunteers ranging in age from 21 to 42 years and weighing between 125 and 220 lb. (about 56.6 and 99.7 kg, respectively). They were selected on the basis of a complete medical history to exclude those having a history of hematologic, hepatic, or renal disease and those with a history of allergic sensitivity to penicillins and cephalosporins. One group of 20 healthy males participated in the intravenous comparative study of cefazolin and cephalothin; the second group participated in the intramuscular study. On the first test day in each study, 10 subjects 1 g of cefazolin by injection and the other 10 received 1 g of cephalothin.
On the second test day (72 h later), cefazolin was given to the test subjects who had received cephalothin, and vice versa. Cefazolin and cephalothin vials were reconstituted with water for injection, USP, before administration.
Blood specimens were collected at 0 h and at 5, 15, 30, 60, 120, and 240 min after intravenous injection. Blood specimens were collected at 0, 0.5, 2, 4, 6, 8, 10, and 12 h after intramuscular injection.
Urine was collected at pre-drug time, 0 to 2, 2 to 4, 4 to 6, and 6 to 12 h after intravenous injection and at pre-drug time, 0 to 2, 2 to 4, 4 to 6, 6 to 12, and 12 to 24 h after intramuscular injection.
Blood and urine samples were collected, frozen, and then analyzed for drug concentration by a Bacillus subtilis agar disk plate method (5).
RESULTS
Intravenous administration. Semilog plots of average serum levels of cefazolin (17 subjects) and cephalothin (20 subjects) after a 1-g intravenous injection versus time are shown in Fig. 1  and 2 . The averages are a good representation of the data of all individual subjects.
Pharmacokinetic analysis was carried out on all individual subjects; the average parameters calculated were very close to the parameters calculated from the plots of average drug levels in the serum so that the parameters used for the discussion in this paper will be those calculated from plots of average drug levels in the serum. Figures 1 and 2 (5) The individual rate constants for cefazolin and cephalothin and the ,B-phase half-lives (commonly termed "biological half-lives") are listed in Table 2 .
The rate constants k,, and k21 in Table 2 were greater for cefazolin than for cephalothin, and the elimination rate constant was approximately three times less for cefazolin. than for cephalothin.
The serum-tissue distribution of cefazoliri and cephalothin can be estimated by calculating the fraction of the administered intravenous dose in the peripheral and central compartments at various times. The fraction in the peripheral and central compartments can be calculated from equations 6 and 7, respectively, arid the parameters listed in Tables 1 and 2 (15):
AC= [(a ) Urinary recoveries of cefazolin and cephalothin after intravenous administration in a time period of 0 to 12 were 75.5 and 37.5%, respectively. Nicholas et al. (10) and Kirby et Table 3 , which shows urinary recover- 
The apparent volume of the extravascular tissue compartment, VT, was also estimated by subtracting the volume of the central compartment, Vp, from the apparent volume of the entire body compartment. The ratio VT/VP represents the ratio of the amount of the drug in the extravascular tissue compartment to the amount of drug in the central compartment.
The parameters are listed in Table 4 .
Since serum protein binding is approximately 85% for cefazolin (14) and 65% for cephalothin (7) , the apparent volume of distribution for cefazolin is also lower than that for cephalothin.
The total clearance rates (TCR) for cefazolin and cephalothin were calculated from the pharmacokinetic parameters by using equation 9: TCR = kei Vp (9) and were 3.8 and 19.8 liters/h, respectively. The renal clearance rates (RCR) for cefazolin and cephalothin were calculated by using the fractions of the dose excreted in the urine (f) for subjects 1, 2, 6, and 8 for cefazolin and the fraction of the dose excreted in the urine for 12 and 15 for cephalothin. These data were in agreement with the theoretical fractions of the dose excreted in the urine for cefazolin and cephalothin. The theoretical fractions were generated by a digital computer programed with a two-compartment open model and the rate constants shown in Table 2 . The TCR for cefazolin and cephalothin were multiplied by the fractions of the dose excreted in the urine (f) according to equation 10: RCR = f.TCR = f.Vp.kel (10) and the values were 3.6 and 10.3 liters/h, respectively. The total and renal clearance rates for cefazolin were almost identical and were consistent with the urinary recovery of almost 100% of administered dose in the urine for subjects 1, 2, 6, and 8. The high plasma and renal clearance rates for cephalothin can be attributed to active tubular secretion (7, 8) and the partial conversion of cephalothin to desacetylcephalothin, which also is responsible for 610 RATTIE AND RAVIN ANTIMICROB. AGENTS CHEMOTHER.
on November 3, 2017 by guest http://aac.asm.org/ Downloaded from approximately 60% urinary recovery of the administered dose found with subjects 12 and 15 and which has been demonstrated by Kirby et al. (14) . These data are in -agreement with previously published results (10, 14) .
Intramuscular administration. A semilog plot of average serum levels of cefazolin and cephalothin in 19 subjects after a 1-g intramuscular injection versus time is shown in Fig. 7 . Peak serum concentrations were attained at 1 h for cefazolin (59.0 ± 9.2 ,ug/ml) and 0.5 h for cephalothin (20.0 i 6.4 ,ug/ml) and were three times as high for cefazolin as for cephalothin. Although the serum leveL data fit a two-compartment open model, not enough blood samples were taken during the first 1.5 h, and therefore graphic dissection of the curves was not possible and absorption rate constants could not be calculated. The terminal data points on the serum concentration time plots were used to calculate the biological half-lives of cefazolin and cephalothin, and the mean halflives were found to be 119 and 43.5 min, respectively, after intramuscular administration. Tables 5 and 6 The mean serum half-life of 39.3 min after intravenous injection of 1 g of cephalothin is comparable with that of 43.5 min found after intramuscular injection of the drug. In contrast, the mean serum half-life of 87 min after intravenous injection of lg of cefazolin compared with that of 119 min after intramuscular injection suggests that cefazolin, which is 85% protein bound, may be bound to proteinaceous muscle tissue, which may prolong its release from the site of injection. Similar results have been obtained with cephalexin (4). The areas under the serum level time curves were determined by the trapezoidal rule for cefazolin and cephalothin after intramuscular administration. For cefazoIin, the areas under the curves were 
